Synthesis and Antibacterial Activity of a New Series of 3&hyphen;&lsqb;3&hyphen;&lpar;Substituted Phenyl&rpar;&hyphen;1&hyphen;Isonicotinoyl&hyphen;1<i>H</i>&hyphen;Pyrazol&hyphen;5&hyphen;yl&rsqb;&hyphen;2<i>H</i>&hyphen;Chromen&hyphen;2&hyphen;one Derivatives
A novel series of 3‐[3‐(substituted phenyl)‐1‐isonicotinoyl‐1H‐pyrazol‐5‐yl]‐2H‐chromen‐2‐one derivatives 4a–k have been synthesized by the reaction of 3‐[2,3‐dibromo‐3‐(substituted phenyl) propanoyl]‐2H‐chromen‐2‐one 3a–k and isonicotinic acid hydrazide in the presence of triethylamine in absolute ethanol, characterized by spectral data and screened for their in‐vitro antibacterialactivity against
The purpose of this study was to evaluate the antimycobacterial activity of various pyrazole derivatives derived from the isoniazid pharmacophore along with coumarin scaffold. The synthesized title compounds (4a-4k) were investigated for their in vitro antimycobacterial activity against Mycobacterium tuberculosis H(37)Rv using Resazurin MIC assay. The synthesized compounds exhibited MIC ranging from 0.625 to 2.50 mu g/ml. Among the series tested, compound 3-[3-(4-fluorophenyl)-1-isonicotinoyl-1H-pyrazol-5-yl]-2H-chromen-2-one 4i was found to be the most active with MIC of 0.625 mu g/ml.